Our business is built on our inherent strengths – KKCG's size and resources, ability to succeed in new markets, expertise in the IT and biotechnology sectors, and experience with effective management.
1/3 our success
daily players
monthly revenues
world games chart
Following the success of Pool Live Tour, a pool game played by more than 100 million players worldwide, the Geewa game development studio has introduced Smashing Four.
2/3 our success
effective in suppressing breast cancer
in the General University Hospital in Prague
with BIOCEV
At the beginning of 2017, scientists from the Biotechnology Institute of the Czech Academy of Science made a breakthrough announcement in the BIOCEV Center. In cooperation with our company Smart Brain, they have developed MitoTam, a substance capable of eliminating tumor cells of one of the most aggressive forms of breast cancer.
3/3 our success
emlpoyees
in revenues in 2018
The ARICOMA Group's establishment marks the completion of the many years during which KKCG focused on the high-potential sector of information technologies. The IT sector currently offers excellent investment opportunities, mainly thanks to the globally growing complexity of ICT solutions and the consequent rise in demand for ICT services.
With a portfolio comprising leading Czech and foreign companies, ARICOMA's strategy is based on the trend that more and more businesses are changing the ways in which they use IT services. The goal is to provide new-generation IT services that guarantee comprehensive coverage for customers' diverse needs. Our flagship, AUTOCONT, specializes in ICT corporate infrastructure and enterprise information systems. We develop software and provide IT outsourcing, ICT security, and cloud services, and our portfolio includes contact centers. We have state-of-the-art data centers in Prague and South Moravia that offer not only secure storage, but also maximum data exploitability. The reliability of our data centers is guaranteed by Tier III certification.
We rely on partnerships with global technology leaders and the extensive expertise of our professionals. Our vision is to create permanent value based on strong and lasting partnerships with the entrepreneurs we support, and with other investors. We are a partner to small and large enterprises in helping them streamline IT operations, reduce operating costs, and improve flexibility to facilitate the implementation of development plans.
Biotechnology research and the transfer of the results derived from it to the marketplace is a very costly, high-risk enterprise. KKCG is one of a small number of Czech corporations engaged in this area. We develop state-of-the-art medical devices that improve the quality of life for patients. We make unique cervical dilators and oversee the development of new products, mainly innovative solutions for tissue regeneration and augmentation and eye surgery. Our funding provides support for clinical trials of MitoTam, a cancer drug developed by Professor Jiří Neužil at the Institute of Biotechnology.
